Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT

The treatment of paroxysmal nocturnal hemoglobinuria has been revolutionized by the introduction of the anti-C5 agent eculizumab; however, eculizumab is not the cure for Paroxysmal nocturnal hemoglobinuria (PNH), and room for improvement remains. Indeed, the hematological benefit during eculizumab t...

Full description

Bibliographic Details
Published in:Frontiers in Immunology
Main Authors: Antonio M. Risitano, Serena Marotta, Patrizia Ricci, Luana Marano, Camilla Frieri, Fabiana Cacace, Michela Sica, Austin Kulasekararaj, Rodrigo T. Calado, Phillip Scheinberg, Rosario Notaro, Regis Peffault de Latour
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-06-01
Subjects:
paroxysmal nocturnal hemoglobinuria
intravascular hemolysis
extravascular hemolysis
complement inhibition
eculizumab
ravulizumab
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2019.01157/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2019.01157/full

Similar Items